Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Study of Irinotecan and Panitumumab

This study has been completed.
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Weijing Sun, MD, FACP, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00836277
First received: February 3, 2009
Last updated: March 18, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2015
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)